Compare BELFA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | HAE |
|---|---|---|
| Founded | 1949 | 1971 |
| Country | United States | United States |
| Employees | 4964 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | N/A | 1996 |
| Metric | BELFA | HAE |
|---|---|---|
| Price | $231.50 | $59.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $174.25 | $84.13 |
| AVG Volume (30 Days) | 68.1K | ★ 540.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ 44.54 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $9.74 | N/A |
| Revenue Next Year | $6.34 | $5.23 |
| P/E Ratio | $40.02 | ★ $24.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.00 | $47.32 |
| 52 Week High | $255.04 | $87.32 |
| Indicator | BELFA | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 51.16 |
| Support Level | $114.22 | $48.47 |
| Resistance Level | N/A | $62.78 |
| Average True Range (ATR) | 11.29 | 1.93 |
| MACD | -0.34 | 0.05 |
| Stochastic Oscillator | 57.44 | 53.53 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.